Corrigendum to “PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor” [Volume 14, Issue 9, September 2021, 101152] (Translational Oncology (2021) 14(9), (S1936523321001443), (10.1016/j.tranon.2021.101152))

Satoko Koga, Hideya Onishi, Shogo Masuda, Akiko Fujimura, Shu Ichimiya, Kazunori Nakayama, Akira Imaizumi, Kenichi Nishiyama, Masayuki Kojima, Kei Miyoshi, Katsuya Nakamura, Masayo Umebayashi, Takashi Morisaki, Masafumi Nakamurab

Research output: Contribution to journalComment/debatepeer-review

Abstract

The authors regret that they missed the below corrections. Abstract: 1P 11th line / Result: 6P second line / Result: 8P first line/ Discussion: 11P second line “autocrine”→“autologous”. The authors would like to apologise for any inconvenience caused.

Original languageEnglish
Article number101344
JournalTranslational Oncology
Volume17
DOIs
Publication statusPublished - Mar 2022

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Corrigendum to “PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor” [Volume 14, Issue 9, September 2021, 101152] (Translational Oncology (2021) 14(9), (S1936523321001443), (10.1016/j.tranon.2021.101152))'. Together they form a unique fingerprint.

Cite this